These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 14694373

  • 1. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S, Tajiri T, Noguchi S, Shono K, Ihara K, Hara T, Suita S.
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [Abstract] [Full Text] [Related]

  • 2. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T, Tanaka S, Higashi M, Kinoshita Y, Takahashi Y, Tatsuta K, Suita S.
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [Abstract] [Full Text] [Related]

  • 3. Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.
    Souzaki R, Tajiri T, Higashi M, Kinoshita Y, Tanaka S, Kohashi K, Tsuneyoshi M, Taguchi T.
    Pediatr Surg Int; 2008 Oct; 24(10):1095-100. PubMed ID: 18726105
    [Abstract] [Full Text] [Related]

  • 4. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH, Tseng YF, Lu MY, Yang YL, Chou SW, Lin DT, Lin KH, Jou ST, Hsu WM, Jeng YM.
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [Abstract] [Full Text] [Related]

  • 5. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R, Tajiri T, Teshiba R, Higashi M, Kinoshita Y, Tanaka S, Taguchi T.
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [Abstract] [Full Text] [Related]

  • 6. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections.
    Thorner PS, Ho M, Chilton-MacNeill S, Zielenska M.
    Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O, Aygun N, Tumer S, Ozer E, Olgun N, Sakizli M.
    Cancer Genet Cytogenet; 2007 Jan 15; 172(2):113-9. PubMed ID: 17213019
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Prognostic significance of MYCN amplification in children neuroblastic tumors].
    Niu H, Xu T, Wang F, Chen Z, Gao Q, Yi P, Xia J.
    Zhonghua Bing Li Xue Za Zhi; 2015 Feb 15; 44(2):111-7. PubMed ID: 25916642
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Identification of MYCN gene amplification in neuroblastoma using chromogenic in situ hybridization (CISH): an alternative and practical method.
    Bhargava R, Oppenheimer O, Gerald W, Jhanwar SC, Chen B.
    Diagn Mol Pathol; 2005 Jun 15; 14(2):72-6. PubMed ID: 15905689
    [Abstract] [Full Text] [Related]

  • 15. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M, Oberthuer A, Fischer M, Skowron M, Oestreich J, Berthold F, Spitz R.
    Diagn Mol Pathol; 2005 Sep 15; 14(3):177-82. PubMed ID: 16106200
    [Abstract] [Full Text] [Related]

  • 16. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T, Hosoi H, Iehara T, Kuwahara Y, Osone S, Tsuchiya K, Ohira M, Nakagawara A, Kuroda H, Sugimoto T.
    J Clin Oncol; 2005 Aug 01; 23(22):5205-10. PubMed ID: 16051962
    [Abstract] [Full Text] [Related]

  • 17. Concomitant DDX1 and MYCN gain in neuroblastoma.
    Defferrari R, Tonini GP, Conte M, Papio F, Sementa AR, Valent A, Schena F, Perri P, Mazzocco K.
    Cancer Lett; 2007 Oct 18; 256(1):56-63. PubMed ID: 17611020
    [Abstract] [Full Text] [Related]

  • 18. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
    Kuzyk A, Booth S, Righolt C, Mathur S, Gartner J, Mai S.
    Genes Chromosomes Cancer; 2015 Oct 18; 54(10):616-28. PubMed ID: 26171843
    [Abstract] [Full Text] [Related]

  • 19. The MYCN enigma: significance of MYCN expression in neuroblastoma.
    Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N.
    Cancer Res; 2006 Mar 01; 66(5):2826-33. PubMed ID: 16510605
    [Abstract] [Full Text] [Related]

  • 20. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S, Ohira M, Nakamura Y, Isogai E, Nakagawara A, Kaneko M.
    J Cancer Res Clin Oncol; 2007 Mar 01; 133(3):185-92. PubMed ID: 17028906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.